SARA ACKERMAN: Open Payments
NPI 1467504845 · LAWRENCEBURG, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$981 in 48 payments from 13 companies in 2025. Trend: 2023 $543 · 2024 $1,104 · 2025 $981
Food & beverage: $886Education: $95
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $205 |
| GlaxoSmithKline, LLC. | 13 | $203 |
| ABBVIE INC. | 12 | $179 |
| Astellas Pharma US Inc | 2 | $115 |
| Novo Nordisk Inc | 3 | $53 |
| Lilly USA, LLC | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| SANOFI-AVENTIS U.S. LLC | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
Products named: TRELEGY ELLIPTA, AIRSUPRA, VRAYLAR, UBRELVY, CAPLYTA, FANAPT, JARDIANCE, TZIELD.
Industry payments across KY — which companies pay providers there.
